Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2019

Autores

Vieira, R (Autor) Outra; Souto, SB (Autor) Outra; Sanchez Lopez, E (Autor) Outra; Machado, AL (Autor) Outra; Severino, P (Autor) Outra; Jose, S (Autor) Outra; Santini, A (Autor) Outra; Silva, AM (Autor) Outra; Fortuna, A (Autor) Outra; Garcia, ML (Autor) Outra; Souto, EB (Autor) Outra

Revista

Título: Journal of Clinical Medicine

Vol. 12 Nº Article 2338

Página Final: 1332

ISSN: 2077-0383

Editora: MDPI

Indexação

ISI Web of Knowledge - 0 Citações

Scopus - 50 Citações

Classificação Científica

CORDIS: Ciências da Saúde

Outras Informações

ID Authenticus: P-00R-5TY

DOI: 10.3390/jcm8091332

Abstract (EN): Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic beta-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 20